
Lonza Successfully Places Inaugural Eurobond

Basel, Switzerland, 8 April 2020 – Lonza has successfully placed its inaugural Eurobond with a coupon of 1.625 percent in the European capital market. Lonza is using the funds to refinance existing debt and for general corporate purposes.

The new Eurobond with a volume of EUR 500 million has a maturity of 7 years. The notes have been offered under a standalone Prospectus and will be listed on the Luxembourg Stock Exchange in denominations of EUR 100,000 by EUR 1,000.

Quote from Rodolfo J. Savitzky, Chief Financial Officer, Lonza:

“The Eurobond has effectively diversified Lonza’s liability portfolio and has allowed access to Lonza’s credit profile for an entirely new group of investors. With the successful issuance of the bond, Lonza has taken the next step in its financing strategy, following on from the inaugural S&P rating and the refinancing of its bank facilities”

Lonza’s issuer ratings is currently BBB+ (Standard&Poors) with a stable outlook.

A consortium comprising of BofA Securities, Citi, Credit Suisse, HSBC and ING were mandated to place the bond as Joint Active Bookrunners. Additionally, BNP Paribas, Commerzbank, Mizuho and UBS were mandated as Joint Lead Managers.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

Lonza Contact Details

Dr. Kristin Koehler

Investor Relations
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

Dr. Sanna Fowler

Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
sanna.fowler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.